ReviewPneumonia (Nathan Qld.)2018
Review in Pneumonia (Nathan Qld.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pneumococcal Meningitis Outbreaks in Africa, 2000-2018: Systematic Literature Review and Meningitis Surveillance Database Analyses.The Journal of infectious diseases · 2021Pooled it
- Upper airways colonisation of Streptococcus pneumoniae in adults aged 60 years and older: A systematic review of prevalence and individual participant data meta-analysis of risk factors.The Journal of infection · 2020Pooled it
- Characteristics of Streptococcus pneumoniae colonising Cypriot children during a period of high PCV10 and PCV13 vaccine coverage: serotypes and antimicrobial resistance.BMC infectious diseases · 2026Article
- Sublingual bivalent vaccination with PspA-C-CPE and Alcaligenes lipid A induces protective immunity against both Streptococcus pneumoniae and Clostridium perfringens.Research square · 2026Article
- Review
- Genomic and statistical models to characterizeMicrobial genomics · 2026Article
- Exploring the impact of oral health and vaccination on pneumonia-causing bacteria: insights from predictive modeling.BMC research notes · 2026Article
- Uncommon pathogen, common activity:Frontiers in public health · 2026Article
- Pneumococcal vaccination in elderly care facilities in Japan: A cross-sectional, web-based survey.Human vaccines & immunotherapeutics · 2025Article
- Article
- Analysis of risk factors for plastic bronchitis induced by Streptococcus pneumoniae in children.BMC infectious diseases · 2025Article
- Two Outbreaks of Invasive Pneumococcal Disease in Nursing Homes in Gipuzkoa, Northern Spain.Vaccines · 2025Article
- Impact of the COVID-19 pandemic on invasive pneumococcal disease in American Indian communities in the Southwest US.Journal of medical microbiology · 2025Article
- Outbreak of Serotype 1 Invasive Pneumococcal Disease, Kibera Urban Informal Settlement, Nairobi, Kenya, 2023.Emerging infectious diseases · 2025Article
- Longitudinal prevalence and co-carriage of pathogens associated with nursing home acquired pneumonia in three long-term care facilities.PLOS global public health · 2025Article
- Post-vaccination Streptococcus pneumoniae colonization and respiratory manifestations in children: A prospective cohort study.PloS one · 2025Observational
- PneusPage: A WEB-BASED TOOL for the analysis of Whole-Genome Sequencing Data of Streptococcus pneumonia.Journal of microbiology (Seoul, Korea) · 2025Article
- Rapid detection ofFrontiers in cellular and infection microbiology · 2025Article
- Does Antibiotic Use Contribute to Biofilm Resistance in Sink Drains? A Case Study from Four German Hospital Wards.Antibiotics (Basel, Switzerland) · 2024Article
- Advances in nucleic acid aptamer-based detection of respiratory virus and bacteria: a mini review.Virology journal · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
background
methodsWe conducted a review of published
resultsA total of 98 articles (86 respiratory; 8 conjunctivitis; 2 otitis media; 1 surgical site; 1 multiple), detailing 94 unique outbreaks occurring between 1916 to 2017 were identified. Reported serotypes included 1, 2, 3, 4, 5, 7F, 8, 12F, 14, 20, and 23F, and serogroups 6, 9, 15, 19, 22. The median attack rate for pneumococcal outbreaks was 7.0% (Interquartile range: 2.4%, 13%). The median case-fatality ratio was 12.9% (interquartile range: 0%, 29.2%). Age groups most affected by outbreaks were older adults (60.3%) and young adults (34.2%). Outbreaks occurred in crowded settings, such as universities/schools/daycares, military barracks, hospital wards, and long-term care facilities. Of outbreaks that assessed vaccination coverage, low initial vaccination or revaccination coverage was common. Most (73.1%) of reported outbreaks reported non-susceptibility to at least one antibiotic, with non-susceptibility to penicillin (56.0%) and erythromycin (52.6%) being common. Evidence suggests transmission in outbreaks can occur through multiple modes, including carriers, infected individuals, or medical devices. Several cases developed disease shortly after exposure (< 72 h). Respiratory outbreaks used infection prevention (55.6%), prophylactic vaccination (63.5%), and prophylactic antibiotics (50.5%) to prevent future cases. PPSV23 covered all reported outbreak serotypes. PCV13 covered 10 of 16 serotypes. For conjunctival outbreaks, only infection prevention strategies were used.
conclusionsTo prevent the initial occurrence of respiratory outbreaks, vaccination and revaccination is likely the best preventive measure. Once an outbreak occurs, vaccination and infection-prevention strategies should be utilized. Antibiotic prophylaxis may be considered for high-risk exposed individuals, but development of antibiotic resistance during outbreaks has been reported. The short period between initial exposure and development of disease indicates that pneumococcal colonization is not a prerequisite for pneumococcal respiratory infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.